GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » DeferredTaxAndRevenue

3SBio (TRSBF) DeferredTaxAndRevenue : $0 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is 3SBio DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

3SBio's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0 Mil.

3SBio DeferredTaxAndRevenue Historical Data

The historical data trend for 3SBio's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio DeferredTaxAndRevenue Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

3SBio DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of 3SBio's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio (TRSBF) Business Description

Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (TRSBF) Headlines

No Headlines